Home › Funds › Hemenway Trust Co LLC › VRTX
Hemenway Trust Co LLC position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Hemenway Trust Co LLC reported holding 57,880 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$30.3M, representing 2.24% of its reported portfolio and ranking #21 among its reported holdings. Hemenway Trust Co LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Hemenway Trust Co LLC's VRTX position evolved
Hemenway Trust Co LLC first disclosed a stake in VRTX in Q3 2023 at 3,766 shares (US$1.3M). The position peaked in Q3 2026 at 57,880 shares, worth US$30.3M. Across 13 filings, Hemenway Trust Co LLC increased the stake 10 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 57,880 shares valued at US$30.3M — an increase of 1,885 shares quarter over quarter.. Notable position changes include a 231% increase in Q1 2024 (shares rose 12% over the following quarter), a 83% increase in Q2 2024 (shares were roughly flat over the following quarter), a 41% increase in Q3 2024 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.77K | $1.31M | New |
| Q4 2023 | 4.68K | $1.91M | Add |
| Q1 2024 | 15.52K | $6.49M | Add |
| Q2 2024 | 28.44K | $13.33M | Add |
| Q3 2024 | 40.12K | $18.66M | Add |
| Q4 2024 | 49.41K | $19.90M | Add |
| Q1 2025 | 54.32K | $26.34M | Add |
| Q2 2025 | 55.52K | $24.72M | Add |
| Q3 2025 | 55.12K | $21.59M | Reduce |
| Q4 2025 | 51.02K | $23.13M | Reduce |
| Q1 2026 | 51.50K | $23.00M | Add |
| Q2 2026 | 55.99K | $27.81M | Add |
| Q3 2026 | 57.88K | $30.26M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 25.97M sh · $13.58B · Q3 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 17.81M sh · $9.31B · Q3 2026
- Invesco Ltd 8.28M sh · $4.33B · Q3 2026
- Capital International Investors 5.06M sh · $2.65B · Q3 2026
- Franklin Resources 4.46M sh · $2.45B · Q3 2026
- LOOMIS SAYLES & CO L P 3.62M sh · $1.89B · Q3 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.56M sh · $1.34B · Q3 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Hemenway Trust Co LLC
FAQ
How long has Hemenway Trust Co LLC held VRTX?
Hemenway Trust Co LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Hemenway Trust Co LLC's current position in VRTX?
As of Q3 2026, Hemenway Trust Co LLC holds 57.88K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $30.26M, representing 2.24% of its reported portfolio and ranking #21.
Has Hemenway Trust Co LLC been buying or selling VRTX?
In the latest 13F filing (Q3 2026), Hemenway Trust Co LLC increased its position in VRTX. The position peaked in Q3 2026 at 57.88K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.